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Abstract A randomized, double-blind, placebo-con-
trolled, cross-over, dose-escalating, single-center study was
conducted to evaluate the safety, tolerability, and pharma-
cokinetic (PK) profile of multiple once-daily (qd) subcuta-
neous (sc) doses of pasireotide in healthy male subjects.
Subjects received pasireotide 50, 200, or 600 lg sc qd for
14 days and placebo in separate sequences. Thirty-three
subjects were randomized. The most frequently reported
drug-related adverse events were injection–site reactions
(n = 18), diarrhea (n = 14) and nausea (n = 10), which
were mostly mild or moderate in intensity. Pasireotide
600 lg sc was associated with pre- and post-prandial ele-
vations in glucose levels relative to placebo; however, this
effect was less pronounced on day 14 compared with day 1.
PK steady state appeared to be achieved after 3 days of
dosing and PK exposures had a moderate accumulation of
20–40 % across doses. Pasireotide demonstrated fast
absorption (Tmax,ss: 0.25–0.5 h), low clearance (CL/Fss:
8.10–9.03 L/h), long effective half-life (T,eff: *12 h,
on average between 9.7 and 13.1 h for 50, 200,
and 600 lg sc qd), and large volume of distribution (Vz/Fss:
251–1,091 L) at steady state. Dose proportionality was
confirmed for Cmax,ss; other PK parameters (Cmax,
AUC0–24 h and AUCtau) were approximately dose propor-
tional. Growth hormone inhibition was observed with
pasireotide 200 and 600 lg sc qd. Gallbladder volume
increased post-prandially with pasireotide 200 and
600 lg sc qd, which appeared to correlate with reduced
levels of cholecystokinin at these doses. Pasireotide was
generally well tolerated up to the tested dose of 600 lg qd,
with a linear and time-independent PK profile after sc qd
dosing in healthy subjects.
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Introduction
Somatostatin receptor subtypes are expressed at high levels in
many tumor cells, which provides the rationale for the
development of medical therapies that specifically target these
receptors [1–3]. Pasireotide (SOM230) is a multireceptor-
targeted somatostatin analog that binds with high affinity to
four of the five somatostatin receptor subtypes (sst1,2,3 and
sst5). Compared with octreotide, pasireotide has a 39-, 30- and
5-fold higher binding affinity for sst5, sst1 and sst3, respec-
tively, and a slightly lower (0.4-times lower) binding affinity
for sst2 [3]. Pasireotide also has a 2-fold higher binding affinity
for sst5 than endogenous somatostatin [4].
The unique binding profile of pasireotide offers potential
therapeutic benefits in the indications associated with sst2
for somatostatin analogs (e.g., octreotide and lanreotide),
such as acromegaly [5, 6] and neuroendocrine tumors
(NET) [7–9]. The multireceptor binding profile of pasire-
otide also provides a rationale for its potential use as a
tumor-targeted management option for diseases in which
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somatostatin receptor subtypes other than sst2 are involved,
e.g., other pituitary adenomas, such as corticotroph ade-
nomas (Cushing’s disease, where sst5 is abundantly
expressed) [4].
Data from pre-clinical studies have shown that the
inhibitory effects of pasireotide on the secretion of growth
hormone (GH) and subsequent production of insulin-like
growth factor 1 (IGF-1) are more potent and are of longer
duration than those of octreotide, and that pasireotide
effectively inhibits the release of adrenocorticotropic hor-
mone (ACTH) from human corticotroph adenoma cells with
or without glucocorticoid pre-treatment [10, 11]. Pasireotide
also significantly suppressed cell proliferation and ACTH
secretion in primary cultures of human corticotroph tumors
[12]. Based on these promising preclinical results, a series of
clinical studies for pasireotide were initiated [13–25].
This article presents the results of a randomized, double-
blind, placebo-controlled, cross-over, dose-escalating, sin-
gle-center Phase I study to evaluate the safety, tolerability,
and pharmacokinetic (PK) profile of multiple once-daily
(qd) subcutaneous (sc) doses of pasireotide in healthy
volunteers.
Methods
Subjects
Healthy male subjects aged 18–40 years with normal
findings from evaluations performed at screening (e.g.,
physical examination, vital signs, electrocardiogram
[ECG], and laboratory tests) were enrolled. Subjects’ body
mass index (BMI) must have been within ±15 kg/m2 of
normal according to the Metropolitan Life Insurance
Tables [26]. Subjects were excluded if they used any pre-
scription drug or over-the-counter medication 14 days prior
to dosing, participated in any clinical investigation within
4 weeks or had donated or lost C400 mL of blood within
8 weeks prior to dosing. Subjects were also excluded if
they had a history of autonomic dysfunction, acute or
chronic bronchospastic disease, clinically significant drug
allergy, or any surgical or medical condition that signifi-
cantly altered the absorption, distribution, metabolism, or
excretion of drugs (e.g., history of cholecystitis or gall-
stones, pancreatic injury or pancreatitis, clinical evidence
of liver disease or injury as indicated by abnormal liver
function tests, history of impaired renal function, evidence
of urinary obstruction or difficult voiding at screening, or
polymorphonuclear leukocytes \1,500/lL or platelets
\100,000/lL at inclusion).
The study was approved by the independent ethics
committee, research ethics board or institutional review
board at the center and complied with the International
Conference of Harmonization (ICH), Harmonized Tripar-
tite Guidelines for Good Clinical Practice, the Declaration
of Helsinki and local laws. All subjects provided written
informed consent.
Study design
Thirty male subjects were to be randomized into one of two
treatment sequences (pasireotide followed by placebo or
placebo followed by pasireotide) within three dose-level
cohorts (n = 10 in each cohort). Subjects received either
pasireotide 50, 200, or 600 lg sc qd. Study medication was
injected in the abdominal wall by study center personnel
each day between 08:00 am and 09:00 am. Subjects
received a daily dose of pasireotide or placebo for 14 days
(treatment period 1). Twenty-four hours after the final drug
administration in treatment period 1, subjects entered a
minimum 14-day washout period. Subjects then received
the other treatment (placebo or, respectively, pasireotide)
for an additional 14 days (treatment period 2; Fig. 1).
Outcomes and assessments
The primary objective was to assess the safety and toler-
ability of multiple doses of pasireotide sc in healthy sub-
jects. Adverse events (AEs) and serious AEs (SAEs) were
recorded throughout the study period. Blood chemistry,
hematology and urine values, laboratory tests, ECG mea-
surements, vital signs and physical examination results
were recorded. The secondary objectives were to charac-
terize the PK profile of multiple doses of pasireotide sc and
to investigate the effects of pasireotide on a number of
pharmacodynamic (PD) parameters as indicators of bio-
logic activity.
Blood samples for the PK evaluation were collected pre-
dose and then 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h
after the first injection in each treatment period. The same
sampling times were used after the last administration in
each treatment period, with additional samples at 36, 48,
72, and 96 h. Blood samples for trough concentrations
were collected pre-dose on days 3, 4, 5, 9, 12, and 13 in
each treatment period. All blood samples were collected by
either direct venipuncture or indwelling cannula inserted in
a forearm vein. A total of 2.5 mL of blood was collected to
yield approximately 1 mL of plasma for analysis of
pasireotide concentration. Laboratory samples for PK
analysis were analyzed by the Department of Bioanalytics
and Pharmacokinetics (Novartis Pharma AG, Basel, Swit-
zerland). Plasma concentrations were determined by a
validated radioimmunoassay (RIA) with a lower limit of
quantification (LLOQ) of 0.03 ng/mL.
PK non-compartmental analysis was performed using
WinNonlin software (version 5.2; Pharsight Corp.,
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Mountain View, CA, USA). PK parameters after the first
administration on day 1 included: maximum (peak)
observed plasma concentration (Cmax), time to reach Cmax
(Tmax), area under the plasma concentration–time curve
from time zero to 24 h (AUC0–24 h), and apparent total
body clearance (CL/F). PK parameters after the last
administration on day 14 included: maximum steady-state
drug concentration (Cmax,ss), minimum concentration at
steady state (Cmin,ss), mean concentration at steady state
(Cavg,ss), time to reach Cmax,ss (Tmax,ss), area under the
plasma concentration–time curve at steady state during one
dosing interval (AUCtau,ss = AUC0–24 h,ss), apparent total
body clearance at steady state (CL/Fss), apparent volume of
distribution at steady state (Vz/Fss), effective half-life
(T,eff) at steady state, accumulation ratio at steady state
(Racc), and peak-to-trough fluctuation at steady state
(=Cmax,ss/Cmin,ss 9 100 %).
The effective half-life (T,eff) of pasireotide was deter-
mined by the following equation [27]: T,eff = ln2s/
ln[Racc/(Racc - 1)], where s (tau) is the dosing interval
(24 h) and Racc is the AUC accumulation ratio,
AUC0–24 h,d14/AUC0–24 h,d1.
For the PD analyses, a GH-releasing hormone (GHRH)
stimulation test was performed between 11:00 am and
12:00 pm on study days 2, 13, 30, and 41. Blood samples
for evaluation of GH levels were collected at 1 and 30 min
before GHRH injection and every 30 min for 2 h (30, 60,
90, and 120 min) after GHRH injection. Glucose, insulin,
cholecystokinin (CCK), glucagon, gastrin, and gallbladder
contraction profiles were measured on days 1, 14, 29, and
42. Measurements were performed at 1 and 30 min before
a standardized meal and every 30 min for 2 h (30, 60, 90,
and 120 min) after a standardized meal. For stool fat
analysis, stools were collected over two 3-day periods
during both treatment periods. Laboratory samples for PD
analysis were processed at the Institute of Experimental
Clinical Research, Medical Research Laboratories (Aarhus
Kommunehospital, Aarhus University Hospital, Aarhus,
Denmark).
Statistical methods
Descriptive statistics were generated for demographic
variables such as age, weight, height, sex and race, as well
as for PK parameters. Dose proportionality for Cmax,
AUC0–24 h, Cmax,ss and AUCtau,ss was evaluated using the
power model (PK = aDoseb), and by comparing the
estimated slope b with the critical region 0.91–1.09 [28].
Results
Thirty healthy male subjects were initially randomized in
the study, with 10 subjects in each treatment group. Of the
30 initial subjects, 25 completed the study and five pre-
maturely discontinued the study. Three additional subjects
were randomized to replace the subjects who dropped out,
with all three completing the study (Table 1). In total, 28
subjects completed the study.
One subject withdrew from the study because of drug-
related vomiting of moderate intensity after receiving the
first dose of pasireotide 600 lg. Four additional subjects
discontinued the study (two withdrew consent, one had a
protocol violation, and one had an AE not related to the
study medication [severe lumbago]). All subjects who
received at least one dose of study drug (n = 33) were
included in the safety and tolerability, and PD evaluations.
The PK analysis population included 31 subjects on day 1
and 28 subjects on day 14.
Randomization
Screening Washout CompletionBaseline –
Treatment period 1
Treatment period 1
Pasireotide
administration Evaluation
Pasireotide sc
50 µg/day
Day –21 to –2 1 to 14 15 to 27 29 to 422815 43 46–1
Placebo
Pasireotide sc
200 µg/day
Placebo
Pasireotide sc
600 µg/day
Placebo
Pasireotide sc
50 µg/day
Placebo
Pasireotide sc
200 µg/day
Placebo
Pasireotide sc
600 µg/day
Placebo
Baseline –
Treatment period 2
Treatment period 2
Pasireotide
administration Evaluation
Fig. 1 Study design
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Safety and tolerability
All subjects except one experienced at least one AE during
the study. The most frequent AEs were gastrointestinal
symptoms (abdominal pain, nausea, vomiting, and diarrhea),
which occurred in a similar percentage of subjects with
pasireotide and placebo, and administration site reactions
(bruising, erythema, irritation, and pruritus), which occurred
predominantly during pasireotide treatment compared with
placebo. The majority of AEs were mild to moderate in
intensity. Ten subjects experienced nausea after receiving
pasireotide 200 or 600 lg. Three subjects receiving 200 lg
reported mild-to-moderate nausea, which started within
10 min of injection and lasted for 10 and 45 min, and 4 days.
At 600 lg, seven subjects experienced mild-to-moderate
nausea, starting approximately 10–15 min after injection
and lasting 1–12 h. Five subjects experienced mild-to-
moderate vomiting, after receiving pasireotide 600 lg. This
occurred primarily on days 1 and 2, although two subjects
experienced vomiting on day 14. Five subjects experienced
severe AEs, including back pain, abdominal distension,
erythema, injection–site irritation and headache, of which
back pain and headache were considered not to be related to
the study drug.
Twenty-seven subjects experienced at least one AE that
was considered to be related to the study drug. The most
frequently reported drug-related AEs were injection–site
reactions, diarrhea, nausea, and vomiting (Table 2). No
SAEs or deaths occurred during this study. There were no
clinically significant abnormalities in the laboratory
parameters, vital signs, or ECG results. No subjects had a
notable QTcF interval after receiving pasireotide, and one
had a QTcB interval increase [30 ms (but \60 ms) with
pasireotide 200 lg. With placebo, two subjects had a
QTcB interval increase [30 ms.
Pharmacokinetics
Pasireotide was absorbed rapidly following the first dosing,
and Cmax was observed mostly within 30 min post-injection
(Fig. 2; Table 3). The systemic drug exposure of pasireotide
appeared to increase proportionally with dose escalation
(Fig. 2; Table 3). It appeared that pasireotide plasma con-
centrations reached steady state after 3 days of daily injec-
tions, as indicated by similar mean trough concentrations
between day 3 and day 14 (Table 3). At steady state, the
peak plasma concentration (Cmax,ss) of pasireotide mostly
occurred within 30 min of administration (Fig. 2; Table 3).
Pasireotide had a long T,eff (approximately 12 h on aver-
age) across the three doses: pasireotide 50 lg: 10.4 ± 3.4 h;
pasireotide 200 lg: 9.7 ± 3.4 h; pasireotide 600 lg:
13.1 ± 3.7 h (Table 3). The CL/Fss was low and similar
across all three doses (range 8.10 ± 2.14 to 9.03 ± 1.37 L/
hour; Table 3). Pasireotide had a large Vz/Fss, which
Table 1 Baseline characteristics for the study population
Total number of subjects (n = 33)
Age (years), mean ± SD 28.3 ± 6.22
Race, n (%)
Caucasian 32 (97)
Other 1 (3)
Height (cm), mean ± SD 180.5 ± 7.05
Weight (kg), mean ± SD 74.5 ± 9.33
BMI (kg/m2), mean ± SD 22.9 ± 2.44
BMI body mass index, SD standard deviation
Table 2 Adverse events with a suspected study–drug relationship
Adverse event, n (%) Pasireotide 50 lg
(n = 11)
Pasireotide 200 lg
(n = 10)
Pasireotide 600 lg
(n = 12)
Placebo
(n = 30)
Injection–site reactions 6 (54.5) 8 (80.0) 4 (33.3) 5 (16.7)
Diarrhea 4 (36.4) 5 (50.0) 4 (33.3) 6 (20.0)
Nausea 0 3 (30.0) 7 (58.3) 0
Vomiting 0 0 5 (41.7) 0
Other GI symptoms (e.g., abdominal
distension)
2 (18.2) 5 (50.0) 7 (58.3) 8 (26.7)
Dizziness 1 (9.1) 0 1 (8.3) 0
Headache 0 2 (20.0) 2 (16.7) 0
Halitosis 0 1 (10.0) 0 0
Dry mouth 1 (9.1) 0 1 (8.3) 2 (6.7)
Pain over kidneys 0 0 1 (8.3) 1 (3.3)
Leg cramps 0 0 1 (8.3) 0
Fainting during injection 0 1 (10.0) 0 0
Muscle fibrillation after injection 0 1 (10.0) 0 0
GI gastrointestinal
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appeared to be increased at higher doses (range up to
1,091 ± 656 L; Table 3). The accumulation of pasireotide
at steady state (Racc) was moderate, approximately 20–40 %
across doses. The steady-state peak-to-trough concentration
fluctuation in each dose cohort was approximately 530 % on
average.
In order to confirm dose proportionality, the 90 %
confidence interval (CI) for the slope was compared to the
critical range of 0.91, 1.09. Dose proportionality was
confirmed for Cmax,ss (slope estimate; 0.99; 90 % CI: 0.91,
1.07); however, other PK parameters, Cmax (slope: 0.92;
90 % CI: 0.82, 1.02), AUC0–24 h (slope: 0.95; 90 % CI:
0.90, 1.00) and AUCtau,ss (slope: 0.97: 90 % CI: 0.90,
1.04), fell slightly outside these limits.
Pharmacodynamics
GH levels
The ability of pasireotide to decrease GH secretion was
demonstrated during a GHRH stimulation test. Inhibition of
GHRH-stimulated GH secretion was observed with pasire-
otide 200 and 600 lg sc (Fig. 3). An average pasireotide
concentration of approximately 0.4 lg/L yielded half of the
maximal GH reduction (EC50), based on an inhibitory Emax
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Table 3 PK parameters on days 1, 3, 4, 5, 9, 12, 13, and 14
Study day PK parameter Pasireotide dose
50 lg qd (n = 11) 200 lg qd (n = 9) 600 lg qd (n = 11)
1 Tmax (h) 0.30 (0.25–0.83) 0.30 (0.25–1.47) 0.25 (0.23–2.00)
Cmax (ng/mL) 1.3 ± 0.4 5.3 ± 1.8 13.1 ± 4.5
AUC0–24 h (h ng/mL) 5.2 ± 1.0 19.8 ± 4.3 54.1 ± 7.0
CL/F (L/h) 9.4 ± 1.9 9.2 ± 1.8 10.4 ± 1.4
3 Cmin,d3 (ng/mL) 0.05 ± 0.05 0.23 ± 0.06 0.65 ± 0.31
4 Cmin,d4 (ng/mL) 0.07 ± 0.05 0.27 ± 0.07 0.64 ± 0.25
5 Cmin,d5 (ng/mL) 0.07 ± 0.05 0.28 ± 0.08 0.69 ± 0.33
9 Cmin,d9 (ng/mL) 0.08 ± 0.05 0.29 ± 0.09 0.73 ± 0.26
12 Cmin,d12 (ng/mL) 0.08 ± 0.06 0.29 ± 0.08 0.77 ± 0.23
13 Cmin,d13 (ng/mL) 0.09 ± 0.05 0.27 ± 0.08 0.78 ± 0.25
14 Tmax,ss (h) 0.35 (0.23, 0.53) 0.25 (0.25, 0.50) 0.50 (0.25, 1.05)
Cmax,ss (ng/mL) 1.39 ± 0.28 5.53 ± 1.22 16.76 ± 4.96
Cmin,ss (ng/mL) 0.08 ± 0.06 0.25 ± 0.10 0.74 ± 0.33
AUCtau,ss (h ng/mL) 6.6 ± 1.8 22.6 ± 3.5 72.9 ± 14.7
Cavg,ss (ng/mL) 0.27 ± 0.08 0.94 ± 0.15 3.04 ± 0.61
CL/Fss (L/h) 8.10 ± 2.14 9.03 ± 1.37 8.54 ± 1.76
Vz/Fss (L) 251 ± 274 1,051 ± 774 1,091 ± 656
T,eff (h) 10.4 ± 3.4 9.7 ± 3.4 13.1 ± 3.7
Racc 1.26 ± 0.17 1.20 ± 0.17 1.36 ± 0.22
Fluctuation (%) 498 ± 129 573 ± 158 525 ± 119
Data are median (range) for Tmax,ss, and arithmetic mean ± SD for all parameters
AUC0–24 h,ss (=AUCtau,ss) area under the plasma concentration–time curve at steady state during one dosing interval (tau) of 24 h, Cavg ss mean
steady-state drug concentration, CL/F apparent total body clearance, CL/Fss apparent total body clearance at steady state, Tmax,ss time to reach
peak or maximum concentration following drug administration at steady state, Cmax,ss maximum steady-state drug concentration, Cmin,ss
minimum steady-state concentration, Racc AUC accumulation ratio, T,eff effective half-life, Vz/Fss apparent volume of distribution at steady state
associated with the terminal disposition phase
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model. GH inhibition was similar on days 2 and 13
(Fig. 3a, b).
Blood glucose metabolism
There were minimal changes in post-prandial glucose
(0–2 h), insulin or glucagon levels on days 1 and 14 in the
pasireotide 50 and 200 lg treatment groups compared with
placebo (Table 4). In the pasireotide 600 lg group, post-
prandial glucose and insulin levels (0–2 h) were higher on
days 1 and 14 compared with placebo; however, post-
prandial glucose levels (0–2 h) in the pasireotide 600 lg
group were lower on day 14 than day 1. There were no
clinically significant shifts in the 2-h post-prandial glucose
levels as all subjects in the study had a shift of\140 mg/dL
with both placebo and pasireotide (50, 200, and 600 lg) on
day 1 and day 14. Subjects receiving pasireotide 600 lg sc
had lower glucagon levels than subjects receiving placebo
on day 1, but a higher glucagon level on day 14, although
there was only one subject in each group.
Cholecystokinin levels
With pasireotide 200 lg, CCK levels were reduced on
average by 38–51 % (i.e., mean decreases of -1 to
-0.6 pmol/L) compared with placebo between 30 min pre-
and post-lunch on day 1. By day 14, there were no
noticeable differences in CCK levels between pasireotide
and placebo subjects relative to day 1. Reductions in CCK
levels for pasireotide 600 lg compared with placebo were
similar at days 1 and 14, with differences ranging on
average between 21 and 53 % (i.e., mean decreases of
0.3–1.3 pmol/L) from 30 min pre-lunch to 120 min post-
lunch.
Gallbladder volume
Gallbladder volume increased for all pasireotide doses
compared with placebo, with a greater volume increase
observed with higher pasireotide doses (Fig. 4). The average
increases were: pasireotide 50 lg: between 1.1 mL (28.6 %)
and 5.3 mL (161.6 %); pasireotide 200 lg: between
15.9 mL (150.3 %) and 18.7 mL (450.1 %); pasireotide
600 lg: between 11.6 mL (1,154.8 %) and 19.4 mL
(711.7 %).
Table 4 Mean AUC(0–2 h) ± SD for post-prandial glucose, insulin, and glucagon levels
Post-prandial glucose
AUC(0–2 h) h mg/dL
Post-prandial insulin
AUC(0–2 h) h mU/L
Post-prandial glucagon
AUC(0–2 h) h ng/L
Day 1 Day 14 Day 1 Day 14 Day 1 Day 14
Placebo (n = 10) 193.1 ± 16.0 183.0 ± 10.6 10.3 ± 10.8 8.3 ± 4.8 133.8 ± 27.3 128.8 ± 22.9
Pasireotide 50 lg (n = 10) 179.6 ± 14.0 186.9 ± 19.0 7.9 ± 5.6 10.4 ± 7.0 132.1 ± 18.8 128.8 ± 19.1
Placebo (n = 8) 194.3 ± 19.7 199.5 ± 20.5 19.3 ± 9.6 19.1 ± 13.1 127.7 ± 22.0 121.8 ± 24.3
Pasireotide 200 lg (n = 8) 195.4 ± 8.2 184.7 ± 16.5 18.0 ± 9.3 20.9 ± 9.8 121.6 ± 29.9 130.1 ± 31.1
Placebo (n = 10) 197.0 ± 15.8 195.3 ± 21.5 26.2 ± 9.0 31.8 ± 15.5 159.9 ± 36.0 139.5*
Pasireotide 600 lg (n = 10) 231.7 ± 46.4 212.8 ± 43.3 36.6 ± 23.8 45.6 ± 30.2 131.5 ± 36.4 150.5*
The post-lunch AUC for blood glucose, insulin, and glucagon is calculated based on the assessments from five scheduled time points (pre-lunch,
30, 60, 90, and 120 min post-lunch) using the linear trapezoidal rule
AUC area under the curve
* Only one patient had available data for assessment of day 14 post-prandial glucagon in the 600 lg cohort
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Stool fat
The difference in the percentage of stool fat increased with
higher pasireotide doses. The differences compared with
placebo were: pasireotide 50 lg: between -0.3 and 2.9 %;
pasireotide 200 lg: between 2.0 and 4.9 %; pasireotide
600 lg: between 4.7 and 7.7 %.
Gastrin and thyroid hormones
No significant differences in gastrin levels and thyroid
hormone levels were observed for any pasireotide sc doses
compared with placebo.
Discussion
This study evaluated the safety, tolerability, and PK of
pasireotide sc in healthy male volunteers. Pasireotide 50,
200, and 600 lg sc administered qd for 14 days was gen-
erally well tolerated. AEs were mostly mild or moderate in
intensity and gastrointestinal in nature. A total of 10 sub-
jects treated with pasireotide 200 or 600 lg experienced
nausea, which occurred within 15 min of injection and
lasted between 10 min and 4 days. In the five subjects who
reported vomiting during the study, this was transient,
occurring predominantly on days 1 and 2. All AEs resolved
without clinical intervention and no SAEs or deaths were
recorded in this study. AEs considered to be potentially
drug related were also mostly gastrointestinal and mild or
moderate in intensity. No clinically significant changes in
laboratory parameters, vital signs and ECG findings were
reported during the study period.
PK steady state seemed to be achieved after 3 days of
daily pasireotide sc injections and PK exposures were
approximately dose proportional on day 1 after a single
dose and on day 14 at steady state. The Tmax and CL/
F values were similar between days 1 and 14, suggesting
linear and time-independent PK of pasireotide sc. In
addition, the approximate 12-h (mean 9.7–13.1 h across
doses) effective half-life (T,eff) of pasireotide is longer
than that of octreotide sc (*1.7 h [14]), which suggests
that it is suitable for a twice-daily dosing regimen. Phase II
and III trials investigating the clinical efficacy and safety of
twice-daily (bid) pasireotide sc, as well as a long-acting
repeatable formulation (pasireotide LAR), in patients with
acromegaly, Cushing’s disease, NET and other solid
tumors that express multiple somatostatin receptor sub-
types are currently ongoing [18–24, 29]. The results of the
Phase I study reported here were obtained (although not
published) prior to the Phase II trials discussed above [18,
19, 23, 24] and contributed toward the establishment of the
pasireotide bid dosing regimen.
As expected for this class of compound, pasireotide had
an effect on glucose metabolism. Single doses of pasireo-
tide 600 lg sc were associated with pre- and post-prandial
elevations in glucose levels relative to placebo on day 1.
Glucose levels on day 14 were lower than on day 1 in
pasireotide 600 lg sc recipients (mean post-prandial glu-
cose AUC(0–2 h) of 212.8 versus 231.7 h mg/dL), but
higher than glucose levels on day 14 in placebo recipients.
This suggests that increases in glucose levels are transient.
Similar elevations in blood glucose levels following
pasireotide administration have been reported in patients
with Cushing’s disease [18]. The potential clinical impact
of pasireotide-associated hyperglycemia in patients with
pre-existing diabetes or glucose intolerance has been dis-
cussed elsewhere in the literature [30]. Compared with day
1, post-prandial insulin levels on day 14 were generally
elevated in all groups. This is in contrast to other studies,
where insulin levels have been observed to be lower in the
post-prandial period [15]. A study in healthy volunteers
confirmed that administration of pasireotide is related to
decreases in insulin secretion, with no changes in insulin
sensitivity [31].
Pasireotide 200 and 600 lg inhibited GHRH-stimulated
GH secretion, as expected for this somatostatin analog.
This effect was similar on days 1 and 14, indicating a
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Fig. 4 Mean gallbladder volume ± SD over time at a day 1 and
b day 14. Placebo treatment is shown as a summary of placebo values
at all three treatment levels
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sustained effect. Gallbladder volume increased for all doses
of pasireotide, with a greater increase observed for higher
pasireotide doses. The post-prandial increase in gallbladder
volume appeared to correlate with reduced levels of CCK
at these doses. The increase in gallbladder volume was
similar in subjects receiving both pasireotide 200 and
600 lg, while CCK levels were reduced to a greater extent
after pasireotide 600 lg than pasireotide 200 lg. This
suggests that only a slight reduction in CCK levels is
sufficient to significantly delay gallbladder contractions, or
it could indicate that pasireotide acts through another
mechanism to decrease contractions. Further studies are
required to confirm this. The incidence of fatty stools was
more prevalent in subjects receiving higher doses of
pasireotide (200 and 600 lg); however, there was no effect
on overall stool weight at any dose. Pasireotide did not
have any effect on gastrin and thyroid hormone secretion.
Conclusions
Pasireotide was generally well tolerated at doses up to
600 lg sc qd and the PK results showed a dose-propor-
tional and time-independent PK profile after qd dosing of
pasireotide sc in healthy male subjects. Based on these
results, further studies have been undertaken to evaluate the
tolerability of pasireotide sc at doses C600 lg adminis-
tered once or twice daily. Investigation is also under way
into the clinical efficacy and safety of pasireotide in
patients with acromegaly, Cushing’s disease, NET, and
other solid tumors that express multiple somatostatin
receptor subtypes.
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